Notice Pursuant to the National Cooperative Research and Production Act of 1993-IMS Global Learning Consortium, Inc., 3820 [2016-01251]
Download as PDF
<![CDATA[
3820
Federal Register / Vol. 81, No. 14 / Friday, January 22, 2016 / Notices
DEPARTMENT OF JUSTICE
Antitrust Division
mstockstill on DSK4VPTVN1PROD with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Consortium Management
Group, Inc. on Behalf of Medical
Countermeasure Systems Consortium
Notice is hereby given that, on
December 8, 2015, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Consortium Management Group, Inc. on
behalf of Medical Countermeasure
Systems Consortium (‘‘CMG–MCSC’’)
has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing (1) the identities
of the parties to the venture and (2) the
nature and objectives of the venture.
The notifications were filed for the
purpose of invoking the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances.
Pursuant to Section 6(b) of the Act,
the identities of the parties to the
venture are: Consortium Management
Group, Inc. on behalf of Medical
Countermeasure Systems Consortium,
Washington, DC; ABL, Inc., Rockville,
MD; Altimmune, Inc., Gaithersburg,
MD; AEQUOR, Inc., Oceanside, CA;
Appili Therapeutics, Inc., Halifax, Nova
Scotia; BalinBac Therapeutics, Inc.,
Princeton, NJ; Battelle, Columbus, OH;
Bavarian Nordic, Kvistgard, DENMARK;
Chemapotheca LLC, Delamar, NY;
CONTINUUS Pharmaceuticals, Inc.,
Woburn, MA; Creare LLC, Hanover, NH;
CUBRC, Inc., Buffalo, NY; Dyne
Immune Institute for Translational
Medicine and Research, Wurtsboro, NY;
DynPort Vaccine Company LLC, a CSC
Company, Frederick, MD; Elusys
Therapeutics, Inc., Pine Brook, NJ;
Emergent Biosolutions Inc.,
Gaithersburg, MD; First Line
Technology, LLC, Chantilly, VA;
GenArraytion, Inc., Rockville, MD;
Ginkgo Bioworks, Boston, MA; IIT
Research Institute, Chicago, IL; Institute
for Therapeutic Innovation, University
of Florida, Orlando, FL; InvivoSciences,
Inc. Madison, WI; Lovelace Biomedical
and Environmental Research Institute
(LBERI), Albuquerque, NM; Luminex
Corporation, Austin, TX; Maurer &
Hutson Consulting, Seattle, WA;
MediVector, Inc., Boston, MA; Mesa
Science Associates, Inc., Frederick, MD;
Molecular Engineering & Sciences
Institute, Seattle, WA; Murtech, Inc.,
Glen Burnie, MD; Nanotherapeutics,
Inc., Alachua, FL; Noninvasix, Inc.,
VerDate Sep<11>2014
16:59 Jan 21, 2016
Jkt 238001
Galveston, TX; Philips Healthcare,
Andover, MA; PnuVax Incorporated,
Kingston, CANADA; The Preclinical
Radiobiology Laboratory, Division of
Translational Radiation Sciences,
Department of Radiation Oncology,
University of Maryland, School of
Medicine, Baltimore, MD; Quintiles,
Inc., Durham, NC; Science Applications
International Corporation, McLean, VA;
Smart Consulting Group, West Chester,
PA; Southern Research, Birmingham,
AL; Southwest Research Institute, San
Antonio, TX; Spero Therapeutics,
Cambridge, MA; Therabron
Therapeutics, Inc., Rockville, MD;
Trideum Biosciences LLC, Huntsville,
AL; University of Pittsburgh Center for
Military Medicine Research, Pittsburgh,
PA; Vaxess Technologies, Inc.,
Cambridge, MA; and Washington to
Washington Consulting, Seattle, WA.
The general area of the CMG–MCSC’s
planned activity is (a) to enter into an
Other Transaction Agreement (‘‘OTA’’)
with the U.S. Government
(‘‘Government’’) for the funding of
certain research, development, testing
and evaluation of prototypes to be
conducted as a collaboration between
the Government and Consortium
Members, to enhance the capabilities of
the Government and its departments
and agencies in the field of
countermeasures against chemical,
biological, radiological and nuclear
threats; (b) to develop countermeasures,
first response and resilient systems; (c)
to participate in the establishment of
sound technical and programmatic
performance goals based on the needs
and requirements of the Government’s
Technology Objectives; (d) to provide a
unified voice to effectively articulate the
global and strategically important role
medical countermeasures play in
current and future national security
objectives; and (e) to maximize the
utilization of the Government’s and
Members’ capabilities to effectively
develop critical technologies which can
be deployed and transitioned.
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2016–01265 Filed 1–21–16; 8:45 am]
BILLING CODE P
PO 00000
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—IMS Global Learning
Consortium, Inc.
Notice is hereby given that, on
December 29, 2015, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), IMS
Global Learning Consortium, Inc. (‘‘IMS
Global’’) has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Cobb County School
District, Smyrna, GA; Duncanville ISD,
Duncanville, TX; EdX Inc., Cambridge,
MA; eSyncTraining, Irvine, CA;
K12.com, Herndon, VA; Motivis
Learning, Salem, NH; Otus, Highland
Park, IL; and Southern New Hampshire
University/College for America,
Manchester, NH, have been added as
parties to this venture.
Also, Saylor Foundation, Washington,
DC; and Blue Canary, Chandler, AZ,
have withdrawn as parties to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and IMS Global
intends to file additional written
notifications disclosing all changes in
membership.
On April 7, 2000, IMS Global filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on September 13, 2000 (65 FR
55283).
The last notification was filed with
the Department on October 13, 2015. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on November 10, 2015 (80 FR
69698).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2016–01251 Filed 1–21–16; 8:45 am]
BILLING CODE P
Frm 00045
Fmt 4703
Sfmt 9990
E:\FR\FM\22JAN1.SGM
22JAN1
]]>Agencies
[Federal Register Volume 81, Number 14 (Friday, January 22, 2016)]
[Notices]
[Page 3820]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-01251]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--IMS Global Learning Consortium, Inc.
Notice is hereby given that, on December 29, 2015, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), IMS Global Learning
Consortium, Inc. (``IMS Global'') has filed written notifications
simultaneously with the Attorney General and the Federal Trade
Commission disclosing changes in its membership. The notifications were
filed for the purpose of extending the Act's provisions limiting the
recovery of antitrust plaintiffs to actual damages under specified
circumstances. Specifically, Cobb County School District, Smyrna, GA;
Duncanville ISD, Duncanville, TX; EdX Inc., Cambridge, MA;
eSyncTraining, Irvine, CA; K12.com, Herndon, VA; Motivis Learning,
Salem, NH; Otus, Highland Park, IL; and Southern New Hampshire
University/College for America, Manchester, NH, have been added as
parties to this venture.
Also, Saylor Foundation, Washington, DC; and Blue Canary, Chandler,
AZ, have withdrawn as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and IMS Global intends to file
additional written notifications disclosing all changes in membership.
On April 7, 2000, IMS Global filed its original notification
pursuant to Section 6(a) of the Act. The Department of Justice
published a notice in the Federal Register pursuant to Section 6(b) of
the Act on September 13, 2000 (65 FR 55283).
The last notification was filed with the Department on October 13,
2015. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on November 10, 2015 (80 FR 69698).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-01251 Filed 1-21-16; 8:45 am]
BILLING CODE P
